Nature Communications (Nov 2017)
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
- Shichun Tu,
- Mohd Waseem Akhtar,
- Rosa Maria Escorihuela,
- Alejandro Amador-Arjona,
- Vivek Swarup,
- James Parker,
- Jeffrey D. Zaremba,
- Timothy Holland,
- Neha Bansal,
- Daniel R. Holohan,
- Kevin Lopez,
- Scott D. Ryan,
- Shing Fai Chan,
- Li Yan,
- Xiaofei Zhang,
- Xiayu Huang,
- Abdullah Sultan,
- Scott R. McKercher,
- Rajesh Ambasudhan,
- Huaxi Xu,
- Yuqiang Wang,
- Daniel H. Geschwind,
- Amanda J. Roberts,
- Alexey V. Terskikh,
- Robert A. Rissman,
- Eliezer Masliah,
- Stuart A. Lipton,
- Nobuki Nakanishi
Affiliations
- Shichun Tu
- Neurodegenerative Disease Center, Scintillon Institute
- Mohd Waseem Akhtar
- Neurodegenerative Disease Center, Scintillon Institute
- Rosa Maria Escorihuela
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Alejandro Amador-Arjona
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Vivek Swarup
- Center for Autism Research and Treatment (CART), University of California
- James Parker
- Neurodegenerative Disease Center, Scintillon Institute
- Jeffrey D. Zaremba
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Timothy Holland
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Neha Bansal
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Daniel R. Holohan
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Kevin Lopez
- Neurodegenerative Disease Center, Scintillon Institute
- Scott D. Ryan
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Shing Fai Chan
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Li Yan
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Xiaofei Zhang
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Xiayu Huang
- Bioinformatics Core Facility, Sanford Burnham Prebys Medical Discovery Institute
- Abdullah Sultan
- Neurodegenerative Disease Center, Scintillon Institute
- Scott R. McKercher
- Neurodegenerative Disease Center, Scintillon Institute
- Rajesh Ambasudhan
- Neurodegenerative Disease Center, Scintillon Institute
- Huaxi Xu
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Yuqiang Wang
- Institute of New Drug Research, Jinan University College of Pharmacy
- Daniel H. Geschwind
- Center for Autism Research and Treatment (CART), University of California
- Amanda J. Roberts
- Department of Neuroscience and Mouse Behavioral Assessment Core, The Scripps Research Institute
- Alexey V. Terskikh
- Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute
- Robert A. Rissman
- Department of Neurosciences, University of California, San Diego, School of Medicine
- Eliezer Masliah
- Department of Neurosciences, University of California, San Diego, School of Medicine
- Stuart A. Lipton
- Neurodegenerative Disease Center, Scintillon Institute
- Nobuki Nakanishi
- Neurodegenerative Disease Center, Scintillon Institute
- DOI
- https://doi.org/10.1038/s41467-017-01563-8
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 12
Abstract
Human MEF2C haploinsufficiency results in Autism Spectrum Disorder (ASD), but it is unclear if the same is true in mice. Here, the authors show that Mef2c +/− mice have behavioral defects and neuronal abnormalities similar to ASD, and symptoms can be ameliorated with the new drug, NitroSynapsin.
